Frankfurt - Delayed Quote EUR

IGM Biosciences, Inc. (1K0.F)

Compare
1.9000
-4.1000
(-68.33%)
At close: January 10 at 3:52:01 PM GMT+1

Key Executives

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Ms. Mary Beth Harler M.D. CEO & Director -- -- 1965
Mr. Misbah Tahir CPA Chief Financial Officer 933.88k -- 1975
Mr. TS Harigopal Senior Vice President of Group Operations -- -- --
Mr. Steven Weber Senior VP, Corporate Controller & Principal Accounting Officer -- -- 1977
Mr. Paul C. Graffagnino J.D. Senior Vice President of Legal Affairs -- -- --
Ms. Suzette Tauber Chief Human Resources Officer -- -- 1964
Dr. Angus M. Sinclair Ph.D. Executive Vice President of Research -- -- --
Dr. Lisa L. Decker Ph.D. Chief Business Officer 515.1k -- 1969
Dr. Marvin S. Peterson Ph.D. Executive Vice President of Process Development & Manufacturing -- -- --
Dr. Elizabeth Haanes J.D., Ph.D. Senior Vice President of Intellectual Property -- -- --

IGM Biosciences, Inc.

325 East Middlefield Road
Mountain View, CA 94043
United States
650 965 7873 https://igmbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
198

Description

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Corporate Governance

IGM Biosciences, Inc.’s ISS Governance QualityScore as of January 1, 2025 is 10. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 10; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 5, 2025 at 10:59 AM UTC - March 10, 2025 at 12:00 PM UTC

IGM Biosciences, Inc. Earnings Date

Recent Events

Related Tickers